**SAFETY EVALUATION OF RITUXIMAB OFF-LABEL USE FOR SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES**

doi:10.1136/ejhpharm-2013-000276.166

P Pascual, P Carmona, J Barral, M Umeren, B Irastorza, A Aranguren, G Lizeaga, A Asensio, E Esnola, K Andueza. Donostia University Hospital, Pharmacy Service, San Sebastián, Spain

**Background** Systemic Autoimmune Rheumatic Diseases (SARDs) are a group of syndromes caused by antibodies inflammation related. Rituximab is a biological drug that targets antigen CD-20 present on the surface of B-Lymphocytes and thus potentially active against SARDs refractory to conventional treatment: steroids and immunosuppressants.

**Purpose** To describe and evaluate safety parameters of the risk management protocol for adults SARDs patients treated with off-label Rituximab.

**Materials and Methods** Descriptive-observational study from January 2011 to July 2012 realised by the Pharmacy and Rheumatology Service. Data were obtained from electronic medical records. Three types of risk management protocol data were evaluated. A) Clinical parameters: infection (including Tuberculosis), cardiovascular disease, severe cytopenia, neoplasia or new neurologic symptoms. B) Complementary tests: hemogram and general biochemistry while on Rituximab. C) Others: adverse events related with Rituximab infusion.

**Results** 21 patients were included (mean age 52.71 ± 16.11 years). Diagnoses were Sjögren's Syndrome (10), Systemic Lupus Erythematosus (4), Mixed Connective Tissue Disease (3), inflammatory myopathy (2), Systemic Sclerosis (1) and Wegener's Granulomatosis (1).

A. Clinical parameters: infection was detected on 5 patients (23%), severe cytopenia in 1 patient (4.7%) and peripheral neurological symptomatology in another one. Nor cardiovascular disease or neoplasia were detected.

B. Complementary tests: patient presented severe thrombocytopenia (platelets < 2.000/mL).

C. Adverse events infusion related: detected on 19% of patients.

**Conclusions** Rituximab off-label use for SARDs has increased over the last years and pharmacovigilance strategies as well as risk management protocols have proved useful identifying risks, controlling adverse events, improving quality of care and integrating Pharmacist into direct patient care.

No conflict of interest.

**SAFETY OF SUNITINIB VS PAZOPANIB IN METASTATIC RENAL CANCER IN A TERTIARY HOSPITAL**

doi:10.1136/ejhpharm-2013-000276.168

M Pérez, T Desongles, H Acosta, J Cotrina, M Villalba, M Galván, E Alfaro. Hospital Universitario Virgen del Rocío, Servicio de Farmacia, Seville, Spain

**Background** Sunitinib and pazopanib are tyrosine kinase inhibitors used in the treatment of metastatic renal cancer. Pazopanib has been approved more recently, so the user experience is not as extensive as with sunitinib.

**Purpose** To evaluate the safety profile of pazopanib and sunitinib in patients with metastatic renal cancer.

To compare the incidence of adverse reactions between the two drugs.

**Materials and Methods** We identified patients treated with sunitinib and pazopanib at the hospital in the past two years, using the pharmacy database.

We looked at the medical records of patients through digital medical records, collecting dose patterns, line of therapy, adverse reactions detected, their severity and if dose reductions were necessary, using Excel.

**Results** A total of 26 patients with metastatic renal cancer were identified: 16 treated with sunitinib and 10 with pazopanib.

Anemia was the most frequent drug-related toxic effect in both treatment groups, with an incidence of 93.75% for sunitinib and 60% for pazopanib.

Nausea/vomiting and diarrhoea were detected in 50% of patients treated with pazopanib. In sunitinib patients nausea/vomiting were detected in 6.25% of patients and diarrhoea was detected in 68.75% of patients.

For patients who received pazopanib, the rate of mucositis was 20%, whereas for those treated with sunitinib it was 75%. Palmar-planter erythrodysesthesia syndrome occurred in 48.75% of those on sunitinib treatment, while none was detected for pazopanib, and the frequency of other skin pigmentation disorders for the two drugs was 62.5% and 30% respectively.

Blood pressure was decompensated in 37.5% of patients treated with sunitinib and 10% of those taking pazopanib, although most patients required antihypertensive drugs to get better control.

Dose adjustment was required of sunitinib in 43.75% of cases and pazopanib in 60% for pazopanib.

No conflict of interest.